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Abstract 25 
Background: Eosinophils play a central role in the propagation of allergic diseases including 26 
asthma. Both recruitment and retention of eosinophils regulate pulmonary eosinophilia but 27 
the question of whether alterations in apoptotic cell clearance by phagocytes directly 28 
contributes to resolution of allergic airway inflammation remains unexplored. 29 
 30 
Objectives: In this study we investigated the role of the receptor tyrosine kinase Mer in 31 
mediating apoptotic eosinophil clearance and allergic airway inflammation resolution in vivo 32 
in order to establish whether apoptotic cell clearance directly impacts upon the resolution of 33 
allergic airway inflammation. 34 
 35 
Methods: Alveolar and bone-marrow macrophages were used to study Mer-mediated 36 
phagocytosis of apoptotic eosinophils. Allergic airway inflammation resolution was modelled 37 
in mice using ovalbumin. To determine apoptotic cell clearance in vivo, fluorescently labeled 38 
apoptotic cells were administered intratracheally or eosinophil apoptosis was driven by 39 
administration of dexamethasone. 40 
 41 
Results: Inhibition or absence of Mer impaired phagocytosis of apoptotic human and mouse 42 
eosinophils by macrophages. Mer-deficient mice displayed delayed resolution of ovalbumin-43 
induced allergic airway inflammation together with increased airway responsiveness to 44 
aerosolized methacholine, elevated bronchoalveolar lavage fluid protein levels, altered 45 
cytokine production and an excess of uncleared dying eosinophils after dexamethasone 46 
treatment. Alveolar macrophage phagocytosis was significantly Mer-dependent, with the 47 
absence of Mer attenuating apoptotic cell clearance in vivo to enhance inflammation in 48 
response to apoptotic cells. 49 
 50 
Conclusions: We demonstrate that Mer-mediated apoptotic cell clearance by phagocytes 51 
contributes to resolution of allergic airway inflammation, suggesting that augmenting 52 
apoptotic cell clearance is a potential therapeutic strategy for treating allergic airway 53 
inflammation. 54 
 55 
 56 
 57 
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 58 
Key Messages 59 
• Mer drives clearance of apoptotic eosinophils, key cells in allergic airway 60 
inflammation. 61 
• Absence of Mer leads to delayed resolution of inflammation and increased airway 62 
resistance in allergic airway inflammation. 63 
• Augmenting apoptotic cell clearance is therefore a potential therapeutic strategy for 64 
treating allergic inflammation. 65 
 66 
 67 
Capsule Summary 68 
Defective apoptotic cell clearance is observed in allergic diseases including asthma, but 69 
whether this directly contributes to pathophysiology is unclear. Using Mer deficient mice, we 70 
demonstrate that impaired apoptotic cell clearance exacerbates allergic airway inflammation. 71 
 72 
 73 
Key Words 74 
Eosinophil, Apoptosis, Phagocytosis, MerTK, Inflammation Resolution, Allergic airway 75 
Inflammation, Airway Resistance. 76 
 77 
 78 
Abbreviations 79 
AC:  Apoptotic cells 80 
AMs:  Alveolar macrophages 81 
BALF:   Bronchoalveolar lavage fluid 82 
BMDMs: Bone marrow-derived macrophages 83 
bmEos: Bone marrow-derived eosinophils 84 
DMEM: Dulbecco's modified Eagle Medium 85 
FCS:  Fetal calf serum 86 
FLT3-L: FMS-like tyrosine kinase 3 ligand 87 
H&E:  Hematoxylin and eosin 88 
IMDM: Iscove’s modified Dulbecco’s medium 89 
i.p.  Intraperitoneal 90 
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i.t.  Intratracheal 91 
LPS:   Lipopolysaccharide 92 
MerKD:  Mer-deficient/kinase dead 93 
OVA:  Ovalbumin 94 
PAS:  Periodic acid-Schiff 95 
PBS:  Phosphate-buffered saline 96 
Ri:  Resolution interval 97 
Pros1:  Protein S 98 
RPMI:  Roswell Park Memorial Institute 1640 medium 99 
SCF:  Stem cell factor 100 
TAM:  Tyro-3/Axl/Mer 101 
TLR:   Toll-like receptor 102 
WT:  Wild type 103 
 104 
 105 
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Introduction 110 
Eosinophils play a major role in the propagation of allergic airway diseases such as asthma1,2. 111 
During inflammation, eosinophils are recruited from the bone marrow and migrate to 112 
inflamed tissue where they can release a range of cytotoxic eosinophil-derived products that 113 
promote inflammation, tissue remodelling, airway hyperresponsiveness and organ 114 
dysfunction3.  115 
 116 
Tissue presence of eosinophils is determined by both recruitment and retention within 117 
inflamed sites. Eosinophil elimination from the lung can be regulated by transepithelial 118 
migration and mucociliary clearance, or by apoptosis and subsequent phagocytosis by 119 
macrophages, dendritic cells and airway epithelial cells, a process termed efferocytosis4. The 120 
relative role and importance of eosinophil apoptosis and efferocytosis in the resolution of 121 
allergic airway inflammation in humans remains controversial5 but several lines of evidence  122 
suggest that these pathways have relevance to allergic disease states. Prolonged eosinophil 123 
longevity (with reduced apoptosis) associates with increasing asthma severity in humans6, 124 
while macrophages from individuals with severe or poorly controlled asthma have defective 125 
efferocytosis7,8. In addition, we have recently shown that driving eosinophil apoptosis with 126 
the flavone wogonin attenuates allergic lung inflammation in mice in vivo9, suggesting that 127 
modulation of eosinophil apoptosis is a bona fide target for treating allergic diseases. The 128 
question of whether alterations in apoptotic cell clearance by phagocytes directly contributes 129 
to resolution of allergic airway inflammation remains to be addressed.  130 
 131 
Although the molecular mechanisms driving changes in eosinophil lifespan and clearance in 132 
vivo remain poorly defined, it is known that glucocorticoids, the main treatment for asthma 133 
and other allergic diseases, induce eosinophil apoptosis and upregulate macrophage 134 
phagocytosis of apoptotic cells in vitro10,11. Glucocorticoid-augmented efferocytosis is 135 
dependent upon Mer11, a member of the Tyro-3/Axl/Mer (TAM) receptor tyrosine kinase 136 
family12. There are two well-defined ligands for Mer, Protein S (Pros1) and Gas6, which can 137 
bridge to phosphatidylserine exposed on apoptotic cells. The importance of TAM receptors 138 
and their ligands in efferocytosis has been demonstrated using Mer-deficient (MerKD) and 139 
triple TAM-deficient mice. These mice are characterised by impaired efferocytosis in 140 
lymphoid tissues, diminished apoptotic germ cell removal by Sertoli cells in the testis and 141 
defective pruning of the photoreceptors in the retina by the retinal pigment epithelial cells13–142 
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. Previous studies have investigated the role of Mer in neutrophil-dominant lung injury 143 
models (induced by lipopolysaccharide (LPS) and bleomycin)16, while Axl downregulation 144 
has been demonstrated in moderate-severe human asthma17. However, the potential role of 145 
Mer in regulating eosinophil clearance and resolution of allergic airway inflammation 146 
remains unexplored. 147 
 148 
In the present study, we investigated Mer-mediated eosinophil efferocytosis and its role in 149 
allergic airway inflammation resolution in vivo, to establish whether apoptotic cell clearance 150 
directly impacts upon the resolution of allergic airway inflammation. Absence or inhibition of 151 
Mer impaired phagocytosis of apoptotic human and mouse eosinophils by macrophages, 152 
while Mer-deficient mice had delayed resolution of ovalbumin (OVA)-induced allergic 153 
airway inflammation.  154 
 155 
  156 
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Methods 157 
Eosinophil isolation 158 
Human granulocytes were isolated from blood of healthy volunteers as described19 (Lothian 159 
Research Ethics Committee (#08/S1103/38; #15-HV-013)). Eosinophils were subsequently 160 
isolated by anti-CD16+ve microbeads (Miltenyi Biotec, #130-045-701) following 161 
manufacturer’s instructions with purity >95% as assessed by cellular morphology of Diff-162 
Quik stained cytocentrifuge preparations. Cells were cultured in Iscove’s modified 163 
Dulbecco’s medium (IMDM; Gibco) with 10% autologous serum (37°C/5% CO2). 164 
 165 
Mouse bone marrow-derived eosinophils (bmEos) were generated from unselected bone 166 
marrow progenitor cells using an extended 14 day version of a described protocol20. Briefly, 167 
bone marrow cells were cultured in Roswell Park Memorial Institute 1640 medium (RPMI 168 
1640; Gibco), supplemented with 20% FCS (fetal calf serum), 100 IU/mL 169 
Penicillin/Streptomycin, 2mM L-glutamine, 25mM HEPES (Sigma), 1x nonessential amino 170 
acids and 1mM sodium pyruvate (both Gibco), 50µM 2-mercaptoethanol, stem cell factor 171 
(SCF; 100ng/mL, PeproTech) and FLT3-ligand (FLT3-L; 100ng/mL, PeproTech) for the first 172 
4 days before switching to media containing IL-5 (10mg/mL, PeproTech) for the remainder 173 
of the culture period. After 14 days, cells were >95% eosinophils as assessed by cellular 174 
morphology and expression of Siglec-F by flow cytometry.  175 
 176 
Macrophage isolation 177 
Mouse bone marrow-derived macrophages (BMDMs) were generated as described21. Tibias 178 
and femurs were flushed with Dulbecco's modified Eagle Medium (DMEM; Gibco) and red 179 
blood cells lysed with ACK lysis buffer (Gibco) prior to passing through a 40µm cell strainer. 180 
Cells were plated onto 15cm cell culture dishes (Corning) in DMEM with 20% FCS, 100 181 
IU/mL Penicillin/Streptomycin and 20% L929 supernatant. Media were replaced after 3 days. 182 
On day 6, differentiated macrophages were washed in phosphate-buffered saline (PBS; 183 
Gibco) and detached using a cell scraper. Cells were plated at 0.7x106/mL in DMEM without 184 
serum for 1 hour to allow adhesion before culturing in DMEM with 10% FCS ± 200nM 185 
dexamethasone for 24 hours prior to experimentation, a widely established protocol to 186 
enhance efferocytosis12,22.  187 
 188 
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Mouse alveolar macrophages (AMs) were obtained by lung lavage with 10mL PBS/0.5mM 189 
EDTA. AMs were centrifuged at 350g for 5 minutes then resuspended in IMDM and 190 
incubated at 150,000 cells per well in a 96 well plate. After 1 hour, culture media was 191 
replaced with IMDM supplemented with 10% FCS prior to overnight incubation. 192 
 193 
In vitro phagocytosis assays 194 
The analysis of phagocytosis of fluorescently-labelled apoptotic cells was performed using a 195 
modified previously described method12. Macrophages were stained with CellTrace Far Red 196 
(Thermo Fisher Scientific) as per manufacturer’s instructions prior to the addition of 197 
apoptotic cells. Human eosinophil constitutive apoptosis was induced by overnight culture, 198 
while apoptosis of mouse bmEos was induced by overnight culture with 1µM budesonide in 199 
the absence of IL-5. Apoptosis was examined by Annexin-V and propidium iodide staining 200 
by flow cytometry. Apoptotic eosinophils were labeled with pHrodo as per manufacturer’s 201 
instructions then washed and resuspended at 4x106/mL (human eosinophils) or 5x106 (mouse 202 
bmEos) in IMDM and co-incubated with macrophages for 1 hour with 33nM Protein S 203 
(Pros1) with or without 1µM BMS777607 (Selleck Chemicals) as per figure legends. After 204 
co-incubation, macrophages were detached with 0.05% trypsin/0.53mM EDTA and 205 
phagocytosis assessed by flow cytometry (BD LSR Fortessa, BD Biosciences)23,24.  206 
 207 
Western Blotting 208 
Western blotting was performed as described25,26. Briefly, BMDMs were lysed in 0.1% 209 
Nonidet P40 containing a protease inhibitor cocktail26.  Lysates were separated on a 12% 210 
Tris-HEPES Precise gel (Thermo Fisher Scientific) and transferred electrophoretically onto 211 
polyvinylidene difluoride (PVDF) membranes (Merck Millipore). Membranes were blocked 212 
with 5% non-fat milk (Marvel) in Tris-buffered saline (TBS)/0.1% Tween-20 before 213 
incubation with primary antibodies directed against Mer (1:000; AF591, R&D Systems) and 214 
β-actin (1:50,000; A1978, Sigma). This was followed by horseradish-peroxidase-conjugated 215 
secondary antibodies (1:2500; Dako) and incubation with ECL prime (GE Healthcare). Blots 216 
were exposed to light-sensitive film (MOL7016, SLS) and processed through an X-ray 217 
developer (Ecomax Processor, Photo Imaging Systems Ltd.). 218 
 219 
In vivo model of allergic airway inflammation 220 
Experiments were performed in accordance with the UK Home Office Animals (Scientific 221 
Procedures) Act 1996, following review by local ethics committee. Wild type control (WT; 222 
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C57BL/6, Charles River Laboratories) and MerKD mice27 (C57BL/6 background) were bred 223 
and maintained in specific pathogen-free conditions. Genotypes were confirmed prior to 224 
experimental procedures, with 6-8 week old mice used for in vitro experiments and 8-16 225 
week old female mice used for in vivo experiments. OVA-induced allergic airway 226 
inflammation was modelled as described9.  Briefly, mice were sensitized by intraperitoneal 227 
(i.p.) alum-precipitated (Alum Imject, Pierce Biotechnology) ovalbumin (OVA, Sigma; 20µg 228 
of OVA and 50µL of alum per mouse) on days 1 and 10 and challenged on days 22, 23 and 229 
24 by intratracheal (i.t.) OVA (50µg). Mice were culled and bronchoalveolar lavage fluid 230 
(BALF) and lung tissue were acquired and processed as described19.  231 
BALF cells and lung interstitial inflammatory cells were incubated with combinations of 232 
antibodies against CD45/CD11b/Ly6G/Siglec-F/F4/80, with flow cytometric analysis 233 
performed in the presence of Flow-Check Fluorosphere counting beads (Beckman Coulter) to 234 
allow quantification of cell numbers. The resolution interval (Ri; the time for eosinophil 235 
numbers to decline to half-maximal numbers) was calculated as previously described28. 236 
BALF cytokines and mucus (MUC5AC) were quantified by ELISA (R&D Systems or Caltag 237 
Medsystems) or by forward phase protein microarray and expressed as either relative to 238 
lavage fluid control (PBS) or as relative expression in the MerKD mice compared to wild type 239 
controls at day 7 post OVA challenge (as indicated in the figure legends).  240 
Lungs from separate animals were fixed in 10% formalin (Sigma) prior to sectioning and 241 
staining with hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS). Histological 242 
scoring of alveolar and interstitial inflammatory cell infiltration was quantified after analysis 243 
by two independent, blinded observers, with quantification of airway mucus production 244 
performed using the mucus-goblet index as described9.  245 
Airway responsiveness to aerosolized methacholine was assessed in anesthetised and 246 
mechanically ventilated WT and MerKD mice after sensitization and challenge with OVA 247 
(Buxco Research Systems, Wilmington, NC). Lung resistance was determined and expressed 248 
relative to baseline values in the absence of methacholine with nebulized phosphate-buffered 249 
saline given as vehicle. Airway resistance, in the absence of methacholine challenge, was 250 
measured in OVA-naïve WT and MerKD mice. 251 
In separate experiments dexamethasone (2mg/kg) was administered i.p. on day 3 post-OVA 252 
to induce eosinophil apoptosis, prior to quantification of BALF apoptotic eosinophil number 253 
by Annexin-V binding (of CD45+ve/CD11b+ve/Ly6G-ve/Siglec-F+ve cells).  254 
 255 
In vivo phagocytosis experiments  256 
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Following isolation from peripheral blood human granulocyte apoptosis was induced by 257 
overnight culture prior to labelling with CellTracker™ Green as per manufacturer’s 258 
instructions. Apoptosis was confirmed by Annexin-V and propidium iodide staining by flow 259 
cytometry. A total of 100,000 labelled apoptotic human cells were administered i.t. to naïve 260 
WT and MerKD mice. Mice were culled after 0 and 3 hours and BALF retrieved for analysis 261 
of CellTrackerTM Green positive alveolar macrophages (CD45+ve/CD11c+ve/CD11b-ve cells), 262 
uncleared apoptotic cells (mouse CD45-ve/CellTrackerTM Green+ve cells), recruited mouse 263 
granulocytes (CD45+ve/Ly6G+ve cells) and necrotic debris (EpCam-ve/CD11c-ve/F4/80-ve low 264 
SSC/FSC events).  265 
 266 
Data analysis 267 
Data were analysed using Graphpad Prism (v5) with flow cytometry data analysed using 268 
FlowJo software (Treestar). All data are expressed as mean ± SEM and analysed by Student’s 269 
t-test or analysis of variance (ANOVA) as appropriate with significance accepted at P <0.05. 270 
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Results 271 
Mer deficiency delays the resolution of allergic airway inflammation 272 
To investigate the role of apoptotic cell clearance in the resolution of allergic airway 273 
inflammation, wild type (WT) and Mer deficient (MerKD) mice were sensitized and 274 
challenged with OVA prior to acquisition of tissue on days 1, 3, 7 and 10 post-OVA 275 
challenge (Figure 1A). While both WT and MerKD mice had similar peak BALF eosinophil 276 
numbers at day 3 post-OVA (1.27±0.12 vs. 1.12±0.23 x106/mL), delayed resolution of 277 
eosinophilic inflammation was observed in the MerKD mice at day 7 (Figure 1B and 1C). This 278 
revealed a ∆ change in BALF eosinophil numbers between day 3 and day 7 of 1.79x105/day 279 
in the WT mice vs. 0.63x105/day in the MerKD mice, with a resolution interval (Ri) that was 280 
prolonged by 2 days in the MerKD mice (6.5 days vs. 8.5 days). Interestingly, numbers of 281 
interstitial eosinophils were similar at day 7 (0.58±0.06 vs. 0.73±0.12 x106/mL; Figure 1D). 282 
Similarly, H&E stained lung sections demonstrated predominantly perivascular 283 
inflammation, with no significant differences between WT and MerKD mice (Figure 1E-G). 284 
 285 
The functional consequences of the delayed inflammation resolution in the MerKD mice were 286 
explored by measuring airway responsiveness in anesthetized, mechanically ventilated mice 287 
in response to aerosolized methacholine. MerKD mice that had been sensitised and challenged 288 
with OVA had increased airway resistance (Figure 2A). Baseline airway resistance (in the 289 
absence of methacholine) was unaltered in naïve MerKD mice (Figure S1) confirming that the 290 
observed increase in airway resistance was not innate, but specific to the presence of allergic 291 
airway inflammation. Airway mucus production was similar in both WT and MerKD mice 292 
(Figure 2B-E), although BALF total protein was increased in MerKD mice (671.7±99.9 vs. 293 
990.0±28.8 µg/mL, P<0.05), consistent with the increased inflammation observed (Figure 294 
2F). 295 
 296 
Enhanced cytokine production is not a major feature of allergic inflammation in MerKD 297 
mice 298 
Given that signalling via TAM receptors, including Mer, acts to suppress pro-inflammatory 299 
cytokine production29, we analysed BALF cytokines to examine whether raised levels of 300 
cytokines were present in the MerKD mice and contribute to excess inflammation. Alterations 301 
in BALF proteins and cytokines were investigated by analysis of 43 separate targets at four 302 
separate time points. This analysis revealed that the overall pattern of cytokine expression 303 
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was similar between MerKD and WT mice (Figure S2) with 8 cytokines upregulated >10% 304 
and 21 downregulated >10% in the MerKD mice at day 7 (Figure 2G). Despite increased 305 
relative expression of MCP5 (CCL12), RANTES (CCL5) and MCP-1 (CCL2) in the BALF 306 
of MerKD mice at day 7, these chemokines/cytokines were expressed at low absolute levels 307 
(data not shown). Overall, we interpret these data as suggesting that enhanced cytokine 308 
production was not the major mechanism behind the delayed resolution of allergic 309 
inflammation observed in the MerKD mice. 310 
 311 
Mer inhibition or deficiency impairs phagocytosis of apoptotic eosinophils 312 
We next investigated the relevance of Mer-mediated apoptotic eosinophil clearance to the 313 
observed delayed resolution of allergic airway inflammation in MerKD mice. Loss of Mer 314 
expression on macrophages from MerKD mice was confirmed by Western blotting of bone 315 
marrow-derived macrophages (BMDMs) and by flow cytometry of alveolar macrophages 316 
(AMs; Figure S3A-C). WT AMs expressed both Mer and Axl, with Axl expression 317 
unchanged on AMs from MerKD mice (Figure S3B&C). To assess macrophage capacity for 318 
efferocytosis, BMDMs (Figure 3A) and AMs (Figure 3B) from WT and MerKD mice were co-319 
cultured with pHrodo-labelled apoptotic eosinophils (Figure S4). To ensure that Mer-320 
dependent efferocytosis was not limited by bridging ligand availability, exogenous Mer 321 
ligand (Protein S; Pros1) was also added to these experiments. Although we observed a 322 
significant component of Mer-independent phagocytosis of apoptotic eosinophils, around 323 
30% of AM phagocytosis was Mer-dependent (Figure 3A&B). Furthermore, AMs treated 324 
with BMS777607 (a c-Met inhibitor that inhibits Axl, Tyro3 and Mer) displayed substantial 325 
inhibition of phagocytosis of apoptotic eosinophils (Figure S3D&E), consistent with the 326 
expression of both Mer and Axl by AMs. Inhibition of BMDM efferocytosis by BMS777607 327 
was less marked, consistent with low level expression of Axl by these cells (data not shown)  328 
and previous data demonstrating that WT and Axl-/- BMDMs have similar rates of 329 
efferocytosis12. 330 
 331 
Mer augments apoptotic cell clearance in vivo to dampen inflammation 332 
To further investigate the role of Mer-mediated engulfment of apoptotic eosinophils in vivo, 333 
the glucocorticoid dexamethasone was administered to OVA-sensitised and challenged mice 334 
at the peak of inflammation (day 3 post-OVA) to induce eosinophil apoptosis10 (Figure 3C). 335 
BALF was acquired at 8, 16 and 24 hours post dexamethasone administration and eosinophils 336 
analysed for evidence of cellular death by Annexin-V binding (Figure S5). This revealed a 337 
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time-dependent increase in the percentage of Annexin-V positive eosinophils seen in BALF 338 
of MerKD mice (4.8±0.5% vs. 9.2±0.6 at 16h, P<0.05) (Figure 3D&E) consistent with a 339 
compromised capacity for eosinophil clearance in the absence of Mer.  340 
Furthermore, direct i.t. administration of labelled  human granulocytes which had undergone 341 
cell death (predominantly apoptosis; Figure S4B) to naïve WT and MerKD mice with tissue 342 
acquisition 3 hours later revealed a significant increase in total BALF cells in the MerKD mice 343 
(Figure 4A). Total BALF cell numbers in the WT mice 3 hours after apoptotic cell 344 
administration were near identical to those of mice that had been administered PBS as a 345 
control, indicating successful clearance of the dead cells in the presence of intact Mer-346 
mediated efferocytosis (Figure 4A). In contrast, increased total numbers of cells were 347 
observed in the MerKD mice suggesting that the absence of Mer-mediated efferocytosis 348 
resulted in either failed clearance of the administered apoptotic cells, or recruitment of 349 
inflammatory cells in response to the apoptotic cells, or both. Indeed, alveolar macrophages 350 
(CD45+ve/CD11c+ve cells, Figure S6A) from MerKD mice were characterised by reduced 351 
phagocytosis of the administered apoptotic cells in vivo (Figures 4B&C). Minimal 352 
phagocytosis was observed in lung interstitial macrophages, which also express Mer, from 353 
either WT or MerKD mice. This is consistent with their limited anatomical ability to access 354 
the airway lumen30 (data not shown).  355 
In addition, an increased proportion of the administered apoptotic cells (mouse CD45-356 
ve/CellTracker+ve) were recovered in BALF from MerKD mice (Figure 4D), highlighting the 357 
importance of Mer in mediating apoptotic cell clearance within the airway lumen. In parallel, 358 
an increased percentage of mouse neutrophils (CD45+ve/Ly6G+ve cells) was observed in 359 
BALF from MerKD mice (Figure 4E). This increase in neutrophils was not observed in BALF 360 
recovered from MerKD mice immediately after administration of apoptotic cells (0 hours post 361 
i.t. AC), confirming that neutrophils were recruited in a time-dependent fashion specifically 362 
in the MerKD mice in response to apoptotic cells (Figure 4E). Lastly, a population of low 363 
SSC/FSC events that did not express markers of alveolar macrophage or epithelial cell origin 364 
(EpCam-ve/CD11c-ve/F4/80-ve) was present in the BALF from MerKD mice at 3 hours post i.t. 365 
AC. This population was minimal in the WT mice (Figure 4F and Figure S6B&C) at 3 hours 366 
and minimal at 0 hours in the MerKD mice (data not shown). As uncleared apoptotic cells can 367 
undergo necrosis and release damage-associated molecular patterns leading to the recruitment 368 
of inflammatory cells31, we hypothesised that the low SSC/FSC events were necrotic debris 369 
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from the instilled human granulocytes. Consistent with this, cytocentrifuge preparations of 370 
flow-sorted low FSC/SSC events revealed only cellular debris, in comparison to sorted 371 
CD45+ve/F4/80+ve/CD11c+ve events which clearly demarcated the AM population (Figure 372 
S6D&E). Overall, these data demonstrate that Mer augments apoptotic cell clearance in vivo 373 
to dampen inflammation in response to dying cells. 374 
  375 
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Discussion 376 
Restoration of tissue homeostasis following tissue injury or infection requires termination of 377 
pro-inflammatory signalling and resolution of the inflammatory response. Control of the 378 
resolution process is achieved through a combination of local production of pro-resolution 379 
mediators and apoptosis of recruited inflammatory cells, together with their phagocytic 380 
removal2,32. It is widely accepted that disruption of the processes underlying the timely 381 
resolution of inflammation represents a significant contributory factor to the development of 382 
many inflammatory diseases. One corollary of the pivotal role of dysregulated resolution of 383 
inflammation in disease pathogenesis is that pharmacological modulation of the processes 384 
underlying inflammation resolution represent an attractive strategy to attenuate ongoing 385 
inflammation and accelerate the restoration of tissue homeostasis33,34. In support of this 386 
suggestion induction of apoptosis of either neutrophils or eosinophils in mouse models of 387 
sterile, infectious or allergic inflammation results in reduced inflammation in the airways and 388 
accelerated resolution of inflammation9,19,35. 389 
  390 
Induction of granulocyte apoptosis during inflammation would exert beneficial effects by 391 
directly reducing the overall tissue burden of granulocytes and by limiting the release of 392 
cellular contents that contribute to further tissue damage and the development of persistent 393 
inflammation. Moreover, there may be additional, indirect effects as a consequence of 394 
phagocyte uptake of apoptotic cells. Both “professional” and “non-professional” phagocytes, 395 
including airway epithelial cells, can mediate apoptotic cell clearance through multiple 396 
molecular pathways4,36. Such functional redundancy is thought to reflect the importance of 397 
effective apoptotic cell removal in both homeostatic and inflammatory processes. 398 
Efferocytosis promotes the resolution process by modulation of phagocyte production and 399 
release of anti-inflammatory lipids and cytokines together with suppression of pro-400 
inflammatory cytokine release37,38. In particular, the receptor tyrosine kinases Axl and Mer 401 
mediate clearance of apoptotic cells and membranes by dendritic cells and macrophages. Axl 402 
and Mer exhibit segregation in terms of both expression and activity in a variety of tissue 403 
settings, suggesting that they may perform distinct, yet complementary physiological roles12. 404 
Expression of Axl is strongly induced by TLR-ligands and has been shown to play a major 405 
role in immunosuppression during inflammation. In contrast, Mer is upregulated by liver X 406 
receptor (LXR) ligands and glucocorticoids and is thought to function predominantly in tissue 407 
homeostasis. However, antibody-mediated inhibition of Mer exacerbates inflammation 408 
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following LPS challenge in the lung and augmentation of Mer activity exerts protective 409 
effects16,39. Together with evidence that resolution-phase macrophages express high levels of 410 
Mer, these data suggest that Mer represents an important contributor to the process by which 411 
inflammation normally resolves. 412 
 413 
In this study, we have examined the role of apoptotic cell clearance in the resolution of 414 
inflammation associated with airway allergy. We report a number of novel findings that 415 
extend our understanding of the role of apoptotic cell clearance and Mer-mediated signalling 416 
in inflammation and tissue repair. First, we have demonstrated that the onset of inflammation 417 
in response to OVA challenge in the lung is similar in the absence of Mer, with equivalent 418 
numbers of eosinophils present in the BALF of WT and MerKD mice at day 3.  However, at 419 
later time points (day 7) BALF eosinophils persist in the MerKD mice, together with increased 420 
BALF protein levels. The presence of ongoing inflammation in the absence of Mer 421 
demonstrate that Mer is an important contributor to the efficiency of resolving eosinophilic 422 
inflammation in the airways. Yet, the cellular inflammation in MerKD mice challenged with 423 
OVA returned towards baseline levels by day 10, suggesting that Mer-independent 424 
mechanisms ultimately allow clearance of recruited eosinophils in MerKD mice. The lack of 425 
an effect of loss of Mer upon lung histology and on the numbers of tissue eosinophils may be 426 
due to different mechanisms involved in eosinophil clearance in the airways and in the 427 
interstitial regions. One possibility is that eosinophils exhibit differential susceptibility to 428 
apoptosis in these distinct micro-environments, with airway eosinophils being more sensitive 429 
to undergoing pharmacological induction of apoptosis and subsequent phagocytic clearance 430 
than interstitial eosinophils9. 431 
 432 
Second, contrary to expectation, we did not observe highly elevated pro-inflammatory 433 
cytokine profiles in the MerKD mice at any of the time points examined during the course of 434 
the OVA-induced inflammatory response. Although Mer has been reported to suppress 435 
macrophage TNF production (for example following LPS-induced inflammation in the 436 
peritoneal cavity or in the lung27) it is possible that there may be stimulus-specific effects and 437 
that Mer does not act to counter-regulate a Th2-mediated inflammatory response. 438 
Comparison of expression levels at day 7 revealed that some potentially important 439 
chemokines, such as CCL12 and CCL5 (RANTES), that may act to recruit eosinophils were 440 
present at elevated levels in MerKD mice. However, these chemokines were present at 441 
relatively low levels in both WT and MerKD mice. Similarly, CCL11 and IL-5 that are 442 
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important for eosinophil recruitment and survival were expressed at roughly equivalent or 443 
lower levels in MerKD mice at 7 days. We suggest that these changes in chemokine/cytokine 444 
profiles in the MerKD mice are unlikely to account for the significant differences in eosinophil 445 
numbers observed. Whether Mer-driven resolution of allergic inflammation is associated with 446 
changes in the production of pro-resolving lipid mediators remains to be determined, but in a 447 
model of sterile peritonitis Mer deficiency was associated with reduced levels of lipoxinA4 448 
and Resolvin D140. 449 
 450 
Third, the delayed resolution of inflammation we observe in MerKD mice was accompanied 451 
by increased airway resistance, suggesting that the altered inflammatory response in the 452 
absence of Mer has consequences in terms of lung function. Since airway resistance was 453 
similar in naïve WT and MerKD animals, Mer is unlikely to represent a dominant factor in 454 
regulating airway function under homeostatic conditions. However, perturbation of lung 455 
homeostasis following injury or infection could highlight the role for Mer in regulation of 456 
responses to airway challenge. We did not find any significant changes in airway mucus 457 
production between WT and MerKD mice. It is possible that the differences in airway 458 
inflammation and resistance we have observed do not impact upon mucus production, or that 459 
mucus production is a less sensitive indicator of altered inflammation resolution. 460 
 461 
To investigate the underlying mechanism of Mer in the process of inflammation resolution, 462 
we directly tested whether induction of high levels of apoptosis in eosinophils would reveal 463 
differences in the capacity for clearance of apoptotic cells in MerKD mice. In these 464 
experiments, we treated animals with dexamethasone at the peak of BALF eosinophil 465 
recruitment and tracked the extent of apoptosis present in BALF. We observed approximately 466 
twice as many Annexin-V positive apoptotic eosinophils in MerKD mice when compared with 467 
WT, consistent with a compromised capacity for eosinophil clearance in the absence of Mer. 468 
Glucocorticoids also act to increase Mer expression and function in macrophages which 469 
would further highlight the effect of Mer deficiency in this experimental model. Although our 470 
experiments did not specifically examine the possibility that some dexamethasone-treated 471 
eosinophils were progressing directly to necrosis in vivo without having first undergone 472 
apoptosis (primary necrosis), this represents an important area for future study. Eosinophils 473 
activated by inflammatory mediators can undergo primary necrosis more readily41,42 and our 474 
subsequent experiments demonstrate that apoptotic cells lose their membrane integrity in vivo 475 
to become necrotic (secondary necrosis43), with this effect being marked in the absence of 476 
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Mer-dependent cell clearance. Our data demonstrates that approximately 25-30 percent of the 477 
total capacity for apoptotic cell clearance of bone marrow-derived macrophages or alveolar 478 
macrophages is Mer-dependent. Assuming that Mer mediates a similar proportion of 479 
macrophage capacity in vivo, the extent of apoptosis occurring during resolution of an 480 
inflammatory response may be sufficient to overwhelm the Mer-independent phagocytosis 481 
component leading to enhanced necrosis and amplification of inflammation. 482 
 483 
In this manuscript, we have identified a role for apoptotic cell clearance by Mer in allergic 484 
airway inflammation, demonstrating a delay in resolution of inflammation in MerKD mice. 485 
Together, our data demonstrate that apoptotic cell clearance by phagocytes directly 486 
contributes to the resolution of allergic airway inflammation, suggesting augmentation of 487 
apoptotic cell clearance as a potential therapeutic strategy for treating allergic inflammation 488 
in humans. 489 
 490 
  491 
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Figure legends  633 
 634 
Figure 1. MerKD mice have delayed resolution of allergic airway inflammation in vivo.  635 
(A) Schema of experimental protocol. (B) Bronchoalveolar lavage fluid (BALF) eosinophils 636 
in wild type (WT) and (C) MerKD mice at 1, 3, 7 and 10 days post-ovalbumin (OVA) with 637 
delta (∆) change in eosinophil number between day 3 and day 7 shown (n=7-10). (D) 638 
Interstitial eosinophils at day 7 in WT and MerKD mice (n=6-8). (E-F) Representative lung 639 
sections stained with haematoxylin and eosin (H&E) at day 7 post-OVA from (E) WT and 640 
(F) MerKD mice (scale bar 20µm, x100 original magnification). (G) Quantification of H&E 641 
stained lung sections at 7 days post-OVA treatment (n=5).  Data are expressed as mean ± 642 
SEM, analyzed by 1-way analysis of variance (ANOVA) with Newman-Keuls Multiple 643 
Comparison Test (B, C) or by Student’s t-test (D, G), *p<0.05, **p<0.01, ***p<0.001.  644 
 645 
Figure 2. MerKD mice have exacerbated allergic airway responses. (A) Airway 646 
responsiveness to aerosolized methacholine was assessed in anesthetized and mechanically 647 
ventilated mice at 7 days post-OVA with lung resistance expressed relative to WT baseline 648 
(after nebulization of PBS without methacholine; n=4-5). (B-C) Representative day 7 lung 649 
sections stained with periodic acid Schiff (PAS) from (B) WT and (C) MerKD mice (scale bar 650 
20µm, x200 original magnification). (D) Quantification of mucus production at day 7 as 651 
assessed by the mucus-goblet index (MGI) on PAS stained lung tissue sections (n=5). (E) 652 
Bronchoalveolar lavage fluid (BALF) Mucin5AC (MUC5AC; a mucus glycoprotein) and (F) 653 
total protein content were measured at day 7 post-OVA (n=6-8). (G) Cytokine array showing 654 
day 7 cytokines, chemokines & proteins upregulated in the MerKD mice depicted in red, 655 
those downregulated depicted in blue. Data are expressed as mean ± SEM, analyzed by 2-656 
way analysis of variance (ANOVA) (A) or by Student’s t-test (D, E, F), *p<0.05, **p<0.01. 657 
 658 
Figure 3. Mer deficiency impairs phagocytosis of apoptotic eosinophils.  (A) Phagocytic 659 
capacity of mouse bone marrow-derived macrophages (mBMDMs) from wild type (WT) or 660 
MerKD mice was assessed after co-culture with apoptotic mouse bone marrow-derived 661 
eosinophils in the presence of Protein S (Pros1) (n=4-5). (B) Phagocytic capacity of mouse 662 
alveolar macrophages (mAMs) from WT or MerKD mice was assessed after co-culture with 663 
apoptotic human eosinophils in the presence of Pros1 (n=4-5). (C) Schema of in vivo 664 
experimental protocol. (D) Annexin-V binding of bronchoalveolar lavage fluid (BALF) 665 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 25
eosinophils from WT or MerKD OVA-treated mice at 8, 16 and 24 hours post-dexamethasone 666 
(Dex) treatment (n=4-7). (E) Representative flow cytometry plots (Annexin-V/Siglec-F) from 667 
WT and MerKD mice showing the presence of Annexin-V+ve eosinophils 668 
(CD45+ve/CD11b+ve/Ly6G–ve/ Siglec-F+ve/Annexin-V+ve cells) at 16 hours post-Dex. Data are 669 
expressed as mean ± SEM, analyzed by Student’s t-test (A, B) or 2-way analysis of variance 670 
(ANOVA) with Bonferroni test (D), *p<0.05, ***p<0.001. 671 
 672 
Figure 4. MerKD alveolar macrophages have an impaired engulfment capacity causing 673 
delayed apoptotic cell clearance in vivo. CellTracker™ Green fluorescently labeled 674 
apoptotic human cells (AC) or PBS control were administered intratracheally (i.t.) to naïve 675 
wild type (WT) and MerKD mice, with bronchoalveolar lavage fluid (BALF) collected after 3 676 
hours. (A) Total BALF cell count (B) percentage of alveolar macrophages 677 
(CD45+ve/CD11c+ve/CD11b-ve) phagocytosing labelled apoptotic cells and (C) representative 678 
flow cytometry plots (SSC/CellTracker™ Green) from WT-PBS, or i.t. AC treated WT and 679 
MerKD mice showing CellTracker Green positive (i.e. engulfing) alveolar macrophages. (n=3 680 
WT-PBS; n=6-7 i.t. AC treated WT and MerKD mice). (D) Uncleared apoptotic cells (CD45-681 
ve/CellTracker™ Green+ve cells) in BALF after 3 hours (n=7-9). (E) Recruited mouse 682 
granulocytes (CD45+ve/Ly6G+ve cells) in BALF (n=2-3). (F) Percentage of necrotic debris 683 
present in BALF 3 hours after apoptotic cell administration (n=8-10). Data are expressed as 684 
mean ± SEM, analyzed by Student’s t-test, *p<0.05, ***p<0.001. 685 
 686 
 687 
Supplementary Figure Legends:  688 
 689 
Figure S1. Lack of Mer has no effect on airway resistance in naïve mice. Relative airway 690 
resistance was assessed in anesthetized and mechanically ventilated naïve WT and MerKD 691 
mice in the absence of methacholine and expressed relative to WT mice values. Data are 692 
expressed as mean ± SEM, analyzed by Student’s t-test (n=6-7). 693 
 694 
Figure S2. Time course of BALF cytokines and proteins in wild type and MerKD mice 695 
post-ovalbumin. BALF cytokines and proteins were measured by forward phase protein 696 
array (n≥3 per genotype at each timepoint) with red depicting high expression and green low 697 
expression. 698 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 26
 699 
Figure S3. Confirmation of Mer expression on bone marrow derived and alveolar 700 
macrophages from WT mice and absent expression in MerKD mice. (A) Western blot of 701 
lysates of BMDMs from wild type (WT) or MerKD mice. (B-C) Representative flow 702 
cytometry histograms of AMs isolated from WT and MerKD mice showing (B) Mer and (C) 703 
Axl expression. (D) Bone marrow-derived macrophages (mBMDMs) from WT or MerKD 704 
mice were co-cultured with apoptotic mouse bone marrow-derived eosinophils in the 705 
presence of Protein S (Pros1) with or without BMS777607 (BMS; c-met inhibitor to inhibit 706 
Axl/Tyro3/Mer) (n=4-5). (E) Alveolar macrophages (mAMs) from WT or MerKD mice were 707 
co-cultured with apoptotic human eosinophils in the presence of Pros1 with or without 708 
BMS777607 (n=4-5). Data are expressed as mean ± SEM, analyzed by 2-way analysis of 709 
variance (ANOVA) with Bonferroni test (E, F), **p<0.01, ***p<0.001. 710 
 711 
Figure S4. Analysis of human granulocyte viability, apoptosis and necrosis. (A) 712 
Assessment of viable (Annexin-V-ve/PI-ve), apoptotic (Annexin-V+ve/PI-ve) and necrotic (PI+ve) 713 
human eosinophils by Annexin-V/propidium iodide (PI) staining by flow cytometry prior to 714 
incubation with mouse alveolar macrophages and (B) human granulocytes undergoing 715 
constitutive apoptosis prior to intratracheal administration to mice. Example flow cytometry 716 
plots and cumulative data shown (n=2-4). (C) Representative cytocentrifuge preparation of 717 
aged human eosinophils, black arrow highlights an apoptotic eosinophil with typical cellular 718 
shrinkage and nuclear condensation (scale bar 20µm, x1000 original magnification). 719 
 720 
Figure S5. Flow cytometry gating strategy to identify Annexin-V+ve eosinophils. 721 
Representative flow cytometry plots showing the gating strategy used to identify Annexin-722 
V+ve eosinophils (CD45+ve/CD11b+ve/Siglec-F+ve/Ly6G-ve/Annexin-V+ve cells) within BALF 723 
of OVA-challenged mice.   724 
 725 
Figure S6. Identification of alveolar macrophage phagocytosis of apoptotic cells, 726 
uncleared human granulocytes and necrotic debris in vivo. (A) Representative flow 727 
cytometry plots showing the gating strategy used to identify alveolar macrophages 728 
(CD45+ve/CD11c+ve/CD11b-ve cells) within the bronchoalveolar lavage fluid (BALF) of 729 
apoptotic cell-treated mice. (B-C) Representative flow cytometry plots demonstrating AM 730 
population (red) and low FSC/SSC necrotic debris population (blue) in BALF from (B) WT 731 
and (C) MerKD mice 3 hours after administration of apoptotic cells. (D-E) Cytocentrifuge 732 
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preparations of FACS sorted (D) low FSC/SSC events and (E) CD45+ve/F4/80+ve/CD11c+ve 733 
alveolar macrophages (scale bar 40µm, x1000 original magnification). 734 
 735 
 736 
 737 
 738 
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Figure 4 Felton JM et al.
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Supplementary Figure S1 Felton JM et al.
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Supplementary Figure S2 Felton JM et al.
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Supplementary Figure S4 Felton JM et al.
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